US-based Enable Biosciences Inc., a Stanford and UC Berkeley spinout company focusing on early disease detection, announced on Thursday that it has named Will Robberts as its new chief financial officer (CFO).

The copany says that Robberts has more than two decades of experience and has a range of experience in finance and operational excellence across various industries, including healthcare, software, and technology. He has served as the president and CFO of LIPAC Oncology and TesoRx Pharma. He has served in senior executive leadership and advisory positions at various companies including Thomson Reuters, Esquire Deposition Solutions, KPMG, Softline, and LiveNote. Currently, he serves on the boards of various pharmaceutical and technology companies.

David Seftel, Enable Biosciences MD CEO, said, 'We are thrilled to welcome Will Robberts as our new CFO. His extensive experience and proven track record in finance and operations make him an invaluable addition to our leadership team. He has already significantly impacted the business by securing pivotal funding for the company to support key strategic initiatives.'